BioSpace News Archive

BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the “Business Combination Agreement”), effective as of October 4, 2023.

Cybin Inc. is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the Jefferies Inaugural Biotech CNS/Neuro Summit, taking place October 11-12, 2023 in New York City, NY.

Sosei Group Corporation (“Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD).

Nested Therapeutics today announced it will present preclinical data from its lead candidate, NST-628, a mechanistically novel non-degrading molecular glue that targets multiple nodes in the RAS/MAPK pathway, at the upcoming 2023 AACR-NCI-EORTC International Conference taking place in Boston, Massachusetts from October 11 – 15, 2023.

Kyowa Kirin Co., Ltd. (TSE: 4151) announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product being studied in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany in October 11-14, 2023.

As we approach October’s National Liver Health Awareness Month, Echosens, a manufacturer of non-invasive diagnostic technology, FibroScan®, is urgently calling attention to the importance of prioritizing liver health.

SeqMatic, a leading provider of next-generation sequencing (NGS) and omics services, is proud to announce that it has received Visium Spatial Gene Expression and Visium Spatial Gene Expression for FFPE

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD)

BeyondSpring Inc. announced that on September 28, 2023, it received a written notification from The Nasdaq Stock Market LLC that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550, because the closing bid price of the Company’s ordinary shares was below $1.00 per share for 30 consecutive business days.

Immuneering Corporation (Nasdaq: IMRX) today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston.